A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, ...
Addiction is yet another area where GLP-1s might be effective. Preliminary evidence looks promising, but questions remain.
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Obese people ‘will have to wait’ for Mounjaro amid carefully managed NHS rollout - The decision will help ‘protect other ...
After this, the situation will be reviewed by Nice, who will provide further guidance on the rollout. Mounjaro is a ...
The NHS spending watchdog said about 220,000 people could benefit from the drug in an initial three-year period ...
They need to be prescribed by a healthcare professional alongside programmes that help people lose weight and live healthier ...
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...